课题基金 / 基金详情

项目摘要

项目成果

Markus H. Frank的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract: Human melanoma is a highly aggressive and drug resistant cancer and resistant to systemic therapy once disseminated. Findings of undifferentiated subpopulations with embryonic-like plasticity within this malignancy have pointed to the presence of melanoma stem cells. Recently our laboratory has identified melanoma stem cells characterized by expression of the chemoresistance mediator ABCBS, which are responsible for melanoma progression and can be therapeutically targeted in experimental tumor xenotransplantation models. The molecular and cellular mechanisms by which melanoma stem cells trigger tumorigenesis and promote neoplastic progression are currently unknown. Vasculogenesis and metastasis are phenomena recognized to be critical for tumor growth and neoplastic progression. Despite the significant knowledge about the molecular pathways involved, a specific relationship of cancer stem cells to these processes has not been demonstrated to date. We hypothesize that melanoma stem cells capable of self-renewal and differentiation, which are responsible for tumor growth, may coincide with cancer subpopulations critically involved in tumor vasculogenesis and metastasis and that specific targeting of this cell population and of related molecular pathways could thus provide for novel strategies to eradicate cancers currently resistant to conventional therapy. The specific aims of this proposal are the following: (1) Investigate the relationship between ABCBS+ melanoma stem cells and tumor vasculogenesis and define the molecular mechanisms involved; (2) Define the role of ABCBS+ melanoma stem cells in metastatic neoplastic progression; and (3) Develop novel melanoma stem cell-targeted therapies. Thus, the proposal is highly relevant to efforts directed at developing novel therapeutic strategies to cancer therapy based on selectively targeting vital molecular pathways in cancer stem cells.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
Effects of Malignant Melanoma Initiating Cells on T-Cell Activation.
恶性黑色素瘤起始细胞对 T 细胞激活的影响。
DOI: 10.1007/7651_2015_299
发表时间: 2016
期刊: Methods in molecular biology (Clifton, N.J.)
影响因子: --
作者: [Schatton,Tobias, Schütte,Ute, Frank,MarkusH]
通讯作者: Frank,MarkusH
Multicomponent Therapy for Age-related Skin Stem Cell Deficiency
  • 批准号:
    10707346
  • 项目类别:
  • 资助金额:
    $223.18万
  • 财政年份:
    2022
  • 负责人:
    Markus H. Frank
  • 依托单位:
Multicomponent Therapy for Age-related Skin Stem Cell Deficiency
  • 批准号:
    10494654
  • 项目类别:
  • 资助金额:
    $235.16万
  • 财政年份:
    2022
  • 负责人:
    Markus H. Frank
  • 依托单位:
Stem Cell Integral Membrane Transporter ABCB5 and Dermal Regeneration
  • 批准号:
    10494660
  • 项目类别:
  • 资助金额:
    $58.0万
  • 财政年份:
    2022
  • 负责人:
    Markus H. Frank
  • 依托单位:
Stem Cell Integral Membrane Transporter ABCB5 and Dermal Regeneration
  • 批准号:
    10707397
  • 项目类别:
  • 资助金额:
    $53.9万
  • 财政年份:
    2022
  • 负责人:
    Markus H. Frank
  • 依托单位:
国内基金
海外基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 项目类别:
    面上项目
  • 资助金额:
    58.00万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2013
  • 负责人:
    杨迎伍
  • 依托单位: